A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Chronic Spontaneous Urticaria

In brief

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.

Key facts

Study ID
NCT06445023
Run by
Celldex Therapeutics
People needed
963
Starts
2024-07-11
Expected to finish
2027-04-01
Last updated by the study team
2026-03-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.